NASDAQ$ATRA

Atara Biotherapeutics Inc · Q3 2013 earnings

Q3 2013 earnings · · Investor relations

Headline financials

EPS (adj)

-$696.05

No prior period
Net Income

-$25.4M

No prior period
Operating Income

-$2.55M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$1.68M

No prior period

Revenue & EPS history

Atara · Revenue · Quarterly

$516K

Q1 2026-99.5%vs Q1 2025
Beat estimate in 5 of 13 quarters(38%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

-2.0%

Avg return

Earnings day

+0.3%

Avg return

5 days after

-2.6%

Avg return

30 days after

37%

17 / 46 earnings

Positive

+36.3%

Q2 2022

Best reaction

-24.2%

Q1 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+11.5%+9.6%
Q4 2025-0.6%-16.4%-10.7%
Q3 2025-1.3%+4.3%+43.3%
Q1 2025+4.8%+6.8%+6.3%
Q4 2024+3.9%-9.2%+10.6%
Q3 2024+21.2%+2.0%-7.0%
Q2 2024+5.8%-7.5%+9.6%
Q1 2024-6.3%+6.9%-6.5%
Q4 2023+3.6%+4.0%-1.4%
Q3 2023-7.8%+2.3%-49.8%
Q2 2023-16.4%-7.1%-31.6%
Q1 2023-16.2%-26.5%-43.3%
Q4 2022-12.6%-18.7%-48.2%
Q3 2022-18.0%+8.5%+0.2%
Q2 2022+36.3%+69.8%+32.3%
Q1 2022-5.3%-22.2%-29.7%
Q4 2021-22.6%-32.9%-30.4%
Q3 2021-3.1%-4.4%-8.9%
Q2 2021+0.8%-1.5%+17.9%
Q1 2021-3.9%-3.3%-5.1%
Q4 2020+1.0%-4.2%-14.4%
Q3 2020-5.9%+9.0%+72.0%
Q2 2020+1.9%+3.5%+4.8%
Q1 2020+4.9%+17.5%+11.7%
Q4 2019+8.8%+11.5%-24.4%
Q3 2019+10.2%+6.9%+15.0%
Q2 2019+10.6%+17.3%+16.4%
Q1 2019-24.2%-27.1%-35.6%
Q4 2018-13.3%-8.5%-7.4%
Q3 2018-1.9%-3.5%+5.7%
Q2 2018-2.1%+0.5%+9.1%
Q1 2018-5.8%+1.7%+0.6%
Q4 2017-10.6%-8.6%-9.5%
Q3 2017-6.3%-4.9%+3.1%
Q2 2017-3.3%-3.6%-1.3%
Q1 2017-5.1%-7.0%-10.2%
Q4 2016+21.4%+16.8%-1.2%
Q3 2016+17.2%+45.6%+32.6%
Q2 2016-9.5%-14.7%-14.3%
Q1 2016-5.5%
Q4 2015-18.5%
Q3 2015+4.7%
Q2 2015-11.4%
Q1 2015-1.7%
Q4 2014-5.9%
Q3 2014-15.5%
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro